Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-HSD in NASH and healthy volunteers
NCT04202354Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Mar 2020
- Primary completion
- Sep 2021
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK4532990 in Nonalcoholic steatohepatitis (NASH) (11 cohorts), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events at Day 113. Started Mar 2020; status: completed.
02
Drugs
GSK4532990
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04202354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04202354.